Publications by authors named "J Izbicki"
Objective: The aim was to evaluate the sustainability of the pancreatic Enhanced Recovery After Surgery (ERAS) program and the effect of ERAS items on patient morbidity and hospital stay.
Background: The current ERAS guideline recommendations encompass 27 items to improve recovery after pancreatoduodenectomy (PD).
Methods: Patients who underwent pancreatic resection at the University Hospital Hamburg-Eppendorf between February 2016 and June 2023 were included.
Objective: To describe the evolution of management strategies for neuroendocrine liver metastases (NE LM) and trends in patient outcomes over the preceding 3 decades.
Summary Background Data: Liver metastases are common in neuroendocrine neoplasms and impair prognosis. A broad therapeutic armamentarium has evolved over recent decades but there remains uncertainty regarding optimal treatment selection and sequencing.
Article Synopsis
- International guidelines for imaging follow-up after pancreatic resection for pancreatic ductal adenocarcinoma (PDAC) are inconsistent, leading to varied follow-up strategies globally.
- The study aimed to compare clinical outcomes, including treatment for recurrence and survival rates, between patients who received either symptomatic follow-up or routine imaging after PDAC surgery across 33 international centers.
- A total of 333 patients were analyzed, showing that 29% had symptomatic follow-up while 71% underwent routine imaging, with overall survival rates being examined through statistical methods to identify the impact of the follow-up strategy on patient outcomes.
Objective: To validate the ISGPS definition and grading system of PPAP after pancreatoduodenectomy (PD).
Summary Background Data: In 2022, the International Study Group for Pancreatic Surgery (ISGPS) defined post-pancreatectomy acute pancreatitis (PPAP) and recommended a prospective validation of its diagnostic criteria and grading system.
Methods: This was a prospective, international, multicenter study including patients undergoing PD at 17 referral pancreatic centers across Europe, Asia, Oceania, and the United States.
Article Synopsis
- Researchers developed a novel risk score using molecular markers to predict survival in colorectal cancer patients, moving beyond traditional histopathological methods.
- The study analyzed 1791 patients using immunohistochemistry to measure the levels of H2BUB1, RBM3, and Ki-67, creating a scoring system based on these markers.
- Results indicated that the new risk score could independently predict patient survival, potentially offering a more personalized approach to treatment than classical methods.